Kite and Alpine Immune Sciences Join Forces to Deliver Personalised Cancer Treatments
Curator: Rosalind Codrington, PhD
This curation was attributed to Stephen J. Williams, PhD as a result of 12/7/2022 e-mail:
From: Rosalind Codrington <rcods@hotmail.co.uk>
Date: Wednesday, December 7, 2022 at 8:32 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: WebsiteHello Aviva,
How are you? I hope that you remember me. I used to be a content writer (Rosalind Codrington) at LPBI. Would you be able to remove my profile from your website, please because I am not in science anymore.
Thank you, best regards
Rosalind
Kite Pharma is joining forces with Alpine Immune Sciences to target the immune synapse, the communications area between the antigen presenting cell and the T lymphocyte (FierceBiotech). Their approach is to specifically modify the T cells in the patient’s peripheral blood so that these T cells will target the patient’s tumour. Their engineered Autologous Cell Therapy (eACT) platform, allows them to modify in vitro the patient’s T cells so that they will express either chimeric antigen receptors (CAR) or T cell receptors (TCR).
They have devised single chain antibodies linked to intracellular T-cell activating domains and TCR to specifically target the tumour antigen in the patient. These modifications are introduced into the T-cells via a viral vector to express the CAR and TCR on these cells.
The CAR products are specifically engineered to target cell membrane antigens on the tumour cells, whilst the TCR products are able to target both the cell membrane and the intracellular antigens, giving these products a well rounded approach to targeting both solid tumours and haemtalogical malignancies.
Kite and Alpine Immune Science’s potential for delivering personalised tumour therapy is now being tested in clinical trials.
Leave a Reply